Update regarding the European License Agreement

29 September 2014

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Update regarding the European License Agreement

Plethora Solutions Holdings plc (AIM: PLE) is pleased to announce that further to the announcements made by the Company on 29 August 2014, 16 September 2014 and 18 September 2014, the Cessation Agreements and Patent Transfer Agreements (as defined in the Company's announcements made on 29 August 2014) have completed and the license agreement entered into with Recordati (the "License Agreement") has become effective. Accordingly an initial fee of €5million is now payable to Plethora under the terms of the License Agreement.

About PSD502™ & Premature Ejaculation:

PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. In two large, double blind, pivotal Phase III studies PSD502™ showed a highly significant and clinically meaningful effect increasing mean intravaginal ejaculatory latency time at baseline from 0.5 minutes to 3.2 minutes at week 12. 87% of the patients in the studies were considered as responders with the product being well tolerated with no significant safety issues. PSD502™ also showed positive effects across a wide range of other parameters including partner satisfaction. PSD502™ was approved by the European Commission in November 2013.

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20% to 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

The premature ejaculation market offers significant potential for development and growth given the absence of any widely approved pharmaceutical therapy with good patient acceptance. As a result an effective drug therapy for premature ejaculation may have a commercial potential comparable to erectile dysfunction drugs.

About Plethora

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE LN). Further information is available at www.plethorasolutions.co.uk 

Plethora is focused on commercializing PSD502™ for the treatment of premature ejaculation with strategic marketing partners and obtaining NDA approval for PSD502™ with the FDA.

Enquiries: